Difference between revisions of "Parkin"
m |
|||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| align="center" colspan="2" bgcolor="#ffffff" | [[Image:Parkin.JPG|200px|{{PAGENAME}}]] | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:Parkin.JPG|200px|{{PAGENAME}}]] | ||
| Line 50: | Line 50: | ||
|- | |- | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:50, 10 March 2015
| Parkin | |
|---|---|
| |
| Substrate peptide name | Parkin |
| Synonyms | Ubiquitin E3 ligase PRKN |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | O60260 |
| Reactive glutamines | - |
| Reactive lysines | K49 |
| Substrate sequence | VIFAGKELRND |
| Structure | 1IYF |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:15132984 |
| Notes | |
| Video | 7ebyfxNw2r8XekXX0|300}} |
